Background: The amino sulphonic acid taurine reduces oxidative endoplasmatic
| INTRODUCTION
Portal hypertension (PHT) drives the development of severe complications of chronic liver disease. 1 Portal hypertension accounts for major complications of liver cirrhosis, including ascites formation, variceal haemorrhage, hepatorenal syndrome and hepatic encephalopathy. These entities are major causes of death in these patients. 2 Portal pressure, assessed by hepatic venous pressure gradient (HVPG) measurement, is an excellent predictor for the development of liver-related events and mortality. 3 Thus, current guidelines recommend the assessment of HVPG for prognostic and therapeutic indications in specialised centres with sufficient experience. [4] [5] [6] Clinically significant portal hypertension, defined by a HVPG ≥10 mm Hg is associated with a higher risk of liver-related mortality, development of varices and other PH-related complications. A HVPG ≥12 mm Hg is associated with a relevant risk of bleeding from varices. 7 Nonselective beta-blockers (NSBB) are currently used to medically reduce portal pressure in patients with oesophageal varices. 8 NSBB response is obtained if HVPG decreases to <12 mm Hg or by more than 10% (primary prophylaxis) or 20% (secondary prophylaxis) from baseline. 9 However, only 30%-60% of these patients respond to NSBB treatment, while in up to 30% of the patients, NSBB treatment is discontinued due to side effects. 10 On the one hand, haemodynamic responders to NSBB treatment have a significantly lower risk of variceal bleeding, developing or worsening ascites, spontaneous bacterial peritonitis, hepatic encephalopathy and better survival than nonresponders. 1 On the other hand, NSBBs increase the risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. 11, 12 Taurine is the most abundant free intracellular amino acid in the human body. It is involved in numerous functions-brain development, bile acid metabolism, anti-oxidation, retinal and cardiac function, osmoregulation, calcium-modulation, phospholipid-protein and Zinc interactions. 13 A previous study by Liang et al demonstrated that natural taurine attenuated liver fibrosis and PHT in animal model.
The rats, which were treated with taurine, showed histologically less pronounced liver fibrosis, reduced amount of type I and type III collagen and transforming growth factor beta1 (TGF-b1). 14 Another study reported that taurine reduced oxidative stress which inhibits the activation and transformation of hepatic stellate cells of rats. 15, 16 Stellate cells play a key role in collagen formation during liver fibrosis process.
Thus, taurine showed anti-fibrotic effects, which may reduce PHT.
Taurine was shown to significantly decrease portal venous flow and pressure. Furthermore, taurine improved systemic haemodynamics with increase in the systemic resistance as well as the mean arterial pressure. Consequently, taurine supplementation demonstrated to reduce hepatic fibrosis leading to a pronounced attenuation of PHT in rats. Potential mechanism of action is the decreased amount of NO (nitric oxide) and cyclic guanosine monophosphate measured in hepatic venous blood.
14 Nitric oxide seems to play a role in the development of PHT as increased NO concentration in the splanchnic vessels resulted in hepatic vasodilation and increased portal flow. The exact mechanism of action of taurine on NO metabolism was not uncovered yet. The anti-oxidative effects of taurine obtained by prevention of lipid peroxidation and glutathione depletion could be an explanation. 17 The aim of this proof of concept study was to assess the impact of taurine supplementation on HVPG and systemic haemodynamics, as well as to investigate the tolerability and safety of taurine supplementation in patients with cirrhosis and varices.
| PATIENTS AND METHODS

| Study design and population
Patients with liver cirrhosis and clinically significant PHT (HVPG ≥12 mm Hg) were included in this randomised, controlled, doubleblind trial analysing the effect of taurine supplementation on HVPG.
Hepatic venous pressure gradient measurement was performed prior to inclusion. At baseline HVPG measurement, patients were not on NSBBs. Response to taurine/placebo was evaluated at day 28 by HVPG measurement.
Patients with noncirrhotic PHT, portal vein thrombosis, history of hepatocellular carcinoma, severe cardiac, renal or pulmonal comorbidities as well as patients with active alcohol consumption or anti-viral treatment during the study period were excluded from this study.
Four patients with large varices and HVPG ≥20 mm Hg underwent repeated endoscopic band ligation sessions (until eradication of varices), before enrolment into the study (amendment 2 June 2014). Five patients with previous documented variceal bleeding were band ligated until complete variceal eradication before enrolment into the study.
Enrolled patients got a box with either taurine or placebo. All boxes had the same appearance and were numbered from 1 to 30.
A member of the Department of Clinical Pharmacology not involved in the study had the allocation list and provided the 1:1 randomisation. Physicians, who assessed outcomes, as well as patients were blinded to study medication.
Physicians of the Vienna Hepatic Hemodynamic Lab enrolled and assigned patients to HVPG measurements. All authors had access to the study data and had reviewed and approved the final manuscript.
| Assessed parameters
Epidemiological characteristics were assessed from patient's medical history. The following laboratory parameters were assessed at base- The following gradient programme was used: 2%-15% B in 2.5 minutes, afterwards increased to 50% B within 3 minutes, kept at 50% B for 1.5 minutes for washing and at 4.51 minutes the system was re-equilibrated at 2% B giving a total runtime of 6 minutes.
For the mass spectrometric analysis, the multiple reaction moni- sation mode was used and the ESI spray voltage was 4000 V, gas flow 11 L/min, sheath gas temperature 400°C, sheath gas flow 12 L/min, gas temperature 250°C and nebuliser gas pressure 35 psi.
In order to determine the concentration levels of taurine in the human serum samples a calibration curve was measured at the beginning, in the middle and at the end of the sequence with a relative standard deviation (RSD) % ranging from 11.5% to 3.9% for 0.5 to 10 ng/lL. Human serum samples were measured in duplicates and quantified by the calibration curve.
| Non-invasive measurement of systemic hemodynamics
Systolic and diastolic blood pressures were measured on the upper arm by an automated oscillometric device. Pulse rate and oxygen saturation was automatically recorded from a finger pulse-oxymetric device.
| Sample size
A sample size calculation was performed according to the recommendations given by Stolley et al 22 The calculation was based on a priori assumption of a = 0.05 and b = 0.20. A study in 15 patients per group has the statistical power of 80% to detect a minimum of 10% HVPG difference between groups, with a SD of 1 mm Hg HVPG. 23 
| Statistics
Continuous variables were expressed as mean with SD and categorical variables were described as absolute and relative frequencies.
Treatment effects on hemodynamic parameters were expressed as % change from baseline (D%). T-tests and Fisher's exact tests were used to compare means and proportions respectively. Correlation between variables were calculated using Pearson's correlation coefficient.
The primary endpoint HVPG was measured at baseline and after 
| Ethics
All subjects gave their written informed consent before study inclu- Four of 15 patients of the taurine group achieved a HVPG drop of ≥ 20%. Eight (3 taurine/5 placebo) patients were excluded from the per-protocol efficacy analysis: One subject was withdrawn from the study at his own request (placebo group), 1 subject due to hepatorenal syndrome (placebo group), HCV treatment was initiated in 1 subject (placebo group) during the study period, 1 subject (taurine group) stopped medication by himself at day 2, he died due to sepsis 25 days later. Four subjects disregarded instructions by the study personnel, did not attend at study day 28 (2 in the taurine and 2 in the placebo group) (Figure 1 ).
The efficacy analysis was conducted in the per-protocol study population. Twenty-two patients (8 females and 14 males) with 12
Assessed for eligibility (n = 41) | 89 patients in the taurine group and 10 patients in the placebo group were included in the per-protocol efficacy analysis. The mean age was 51.9 (AE10.9) years. Thirteen patients had alcoholic liver cirrhosis, 6 patients had viral liver cirrhosis, while 3 patients had another aetiology. Two (9%), 14 (64%) and 6 (27%) patients had Child-Pugh score class A, B and C respectively. Baseline characteristics were similar between the 2 groups and are presented in Table 1 . Hepatic haemodynamics assessed during study are shown in Table S1 .
| Efficacy
In the taurine group, mean HVPG decreased from 20 mm Hg (AE4) at baseline to 18 mm Hg (AE4) on day 28 (12% drop; P = .0093). The mean absolute change was 3 mm Hg AE3 and ranged from an increase in 1 mm Hg to a drop of 7 mm Hg.
In the placebo group, mean HVPG changed from 20 mm Hg (AE5) at baseline to 21 mm Hg (AE5) on day 28 (2% increase; P = .4945).
The mean absolute change was 0 mm Hg AE2 and ranged from an increase of 4 mm Hg to decrease of 1 mm Hg.
Seven of 12 patients (58%) on taurine achieved a HVPG response >10%, compared to none in the placebo group (P = .0053).
Four patients (33%) responded to taurine by a HVPG decrease >20% compared to baseline, while no patient responded in the placebo group (P = .0964; Figure 2 ).
In the multivariate analysis, absolute and relative change in HVPG was significantly larger in the taurine group compared to placebo group (P = .0091 and P = .0109 respectively). The change in HVPG did not significantly depend on the baseline HVPG (P = .3237
and P = .5054). We tested whether the regression residuals were normally distributed. The Shapiro-Wilk test was not significant (P = .1878 and P = .2264), therefore, the assumptions of the multivariate linear model are satisfied.
Interestingly, changes in FHVP and WHVP did not change significantly from baseline to day 28 in both groups (Table S2 ).
As described in the methods section, HVPG curves were assessed by 3 physicians independently, all blinded to the study visit and treatment group in order to maximise objectiveness. We performed an sensitivity analysis with patients whose baseline and follow-up HVPG measurements varied less than 3 points between physicians (14 of 22). The treatment effect in the multivariate linear model remained statistically significant (P = .0185 and P = .0174 for absolute and relative change in HVPG respectively), when only these patients were considered for analysis.
There were no significant differences in baseline and follow-up characteristics between responders to taurine and nonresponders (Table S3 ). Table 2 shows that neither taurine nor placebo had an effect on systemic hemodynamics. The association between the changes in taurine and HVPG response is shown in (Figure 3 ). 
| Systemic hemodynamics
| Taurine levels
T A B L E 1 Baseline characteristics
Taurine (n = 12) Placebo (n = 10) P-value
| Safety
Six of the 30 patients (20%; 3 in each treatment group) included in the intention-to-treat analysis reported side effects. Adverse events reported in patients from taurine and placebo group are shown in Table 3 .
None of the patients had to discontinue the study medication due to treatment-related AEs.
Serious adverse events (SAEs) were observed in 3 patients, which
were not considered to be treatment-related. One patient was admitted to hospital due to hepatorenal syndrome with hyperpotassaemia (6.67 mmol/L) at day 6 of placebo. Placebo was stopped at study day 6, the SAE was reported and the patient was excluded from the perprotocol analysis. One patient was admitted for suspected gastrointestinal bleeding. Esophagogastroduodenoscopy and colonoscopy, as well enteroscopy were performed but revealed no bleeding source. The SAE was reported and taurine was continued without interruption.
Taurine was stopped by 1 patient at study day 2. He died due to septicaemia 25 days later. There is no plausible relation between the study medication and the patient's death. The SAE was reported and patient was excluded from the per-protocol analysis.
No study medication-related major incident was reported 6 months after the end of the study. Except one patient, who was lost to follow-up, all patients of the per-protocol sample were alive 6 months after the end of the study.
There were no significant changes in the biochemical parameters shown in during the study period in the intention-to-treat population (Table S4 ).
| DISCUSSION
This is the first study in humans assessing the effect of taurine supplementation on portal pressure. Taurine administration decreased HVPG >10% in 58% of patients. In 33% of patients, HVPG decreased by >20%. The haemodynamic response rate of taurine supplementation is obtained without effects on systemic haemodynamics. Side effects and AEs did not differ between the treatment groups. Dizziness, nausea, emesis or gastrointestinal discomfort were the most common AEs. Three SAEs were observed during study, however, not related to study medication. This suggests, that taurine is well-tolerated by most patients.
In our study, which was the first to analyse serum taurine levels in patients with cirrhosis, the median serum level was only 0.58 ng/lL. This is only one tenth of the serum taurine levels observed in healthy subjects with mean levels reported at 5.3 ng/lL). 24 We cannot conclude that levels of taurine are low in cirrhosis, since there is no contemporary sample of healthy subjects. However, using a dose of 6 g/ d, we observed a 10-fold increase compared to baseline to levels similar to healthy subjects (7.79 ng/lL).
Our study confirms that the dosing of 6 g taurine is welltolerated in patients with cirrhosis. 21 Further dose ranging studies are needed to investigate whether higher taurine doses increase efficacy, or if doses of less than 6 g taurine per day are sufficient to achieve similar response rates, since the results of our analysis on taurine levels revealed a correlation between the increase in taurine levels and the drop in HVPG. Sun et al demonstrated that the dosing of 1.6 g taurine lowers blood pressure and improves vascular function in patients with pre-hypertension. 25 Nonselective beta-blockers are the only recommended medical treatment for PHT. 20 A meta-analysis showed that carvedilol is more effective than propranolol in decreasing PHT. 26 However, even with carvedilol, response rates are only about 50%-60%. 19 Moreover, about 15% of patients may have contraindications and an additional 15% may not tolerate NSBB treatment. 27 Neither bradycardia nor hypotension were observed in patients treated with taurine. Recent studies suggest, that NSBBs should be discontinued in haemodynamically compromised patients with cirrhosis, as they might increase the risks for hepatorenal syndrome and death, due to their negative effects on systemic haemodynamics. 11, 28 No alteration of renal function were recorded in patients treated with taurine. In contrast, NSBBs increase the risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. 11, 12 Therefore, taurine might be a valuable alternative to NSBBs and may be appropriate especially in patients with intolerance or contraindication for NSBBs. In addition, its role as an add-on therapy to NSBB should be investigated.
Also simvastatin might have very similar positive effects on HVPG and liver perfusion. Statins induce an up-regulation of NO production at the liver vasculature through an enhancement in NO synthesis. 29 Abraldes et al reported, that simvastatin lowers in 40% of the patients HVPG of ≥10%. Furthermore, simvastatin lowers in 32% of patients HVPG of ≥20%. 27 However, this study excluded patients with end-stage liver disease (prothrombin rate less than 40%, hepatic encephalopathy II-IV, CPS ≥12). This was probably related to limited data and the contraindication for statin use in end-stage liver disease.
Studies about the impact of taurine on liver disease are scarce.
The few studies which analysed the pathophysiological effect of taurine were performed in animal rodents. Taurine alleviates liver fat by up-regulating hepatic lipid oxidation and ameliorating hepatic lipid efflux. 30 Furthermore, taurine improves hepatic inflammation by decreasing proinflammatory cytokines (IL-1b, IL-6 and TNF-a) and diapedesis of lymphocytes in the liver (iNOS and CRP proteins). 31 Another study reported recently, that taurine might enhance alcohol and fat metabolism, both agents, which might induce liver damage. 32 Taurine seems to be beneficial to overcome muscular cramps in cirrhotics not responding to magnesium in a trial with a single shot of an energy drink, which includes 1000 mg of taurine. 33 Our findings have to be confirmed in larger studies assessing potential beneficial effect of taurine with clinical endoints including the prevention of acute variceal bleeding in the primary and secondary prophylaxis setting. Another study should investigate whether higher doses of taurine increase the rates of hemodynamic response.
A limitation of this study is that patients without varices as well as patients with primary and secondary bleeding prophylaxis were included. Furthermore, 27% of patients did not complete the study. 
